Wei‐Hsun Hsu

961 total citations
20 papers, 501 citations indexed

About

Wei‐Hsun Hsu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Wei‐Hsun Hsu has authored 20 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Wei‐Hsun Hsu's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Wei‐Hsun Hsu is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Research Studies (4 papers). Wei‐Hsun Hsu collaborates with scholars based in Taiwan, Australia and United States. Wei‐Hsun Hsu's co-authors include Derek N.J. Hart, Shang‐Da Huang, Edward Abadir, Mahaveer B. Melwanki, Pablo A. Silveira, Georgina J. Clark, Xinsheng Ju, Giuseppe Giaccone, Ziduo Li and Yisong Wang and has published in prestigious journals such as Scientific Reports, Frontiers in Immunology and Analytica Chimica Acta.

In The Last Decade

Wei‐Hsun Hsu

17 papers receiving 500 citations

Peers

Wei‐Hsun Hsu
Ziyang Wang China
Kazuaki Matsuoka Japan
Miriam E. Mossoba United States
Virginia Belsúe Spain
Max Sauter Germany
Nima Taefehshokr Iran
Guangjian Yang China
Xiaofei Li China
Peter E. Barker United States
Ziyang Wang China
Wei‐Hsun Hsu
Citations per year, relative to Wei‐Hsun Hsu Wei‐Hsun Hsu (= 1×) peers Ziyang Wang

Countries citing papers authored by Wei‐Hsun Hsu

Since Specialization
Citations

This map shows the geographic impact of Wei‐Hsun Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Hsun Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Hsun Hsu more than expected).

Fields of papers citing papers by Wei‐Hsun Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Hsun Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Hsun Hsu. The network helps show where Wei‐Hsun Hsu may publish in the future.

Co-authorship network of co-authors of Wei‐Hsun Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Wei‐Hsun Hsu. A scholar is included among the top collaborators of Wei‐Hsun Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei‐Hsun Hsu. Wei‐Hsun Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chang, Ching‐Cheng, Min‐Shu Hsieh, & Wei‐Hsun Hsu. (2025). An Unusual Case of Acquired AGK-BRAF Gene Fusion in Metastatic EGFR-mutant Lung Adenocarcinoma: A Case Report. Journal of Cancer Research and Practice. 12(1). 20–23.
2.
Hsu, Wei‐Hsun, et al.. (2025). PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC. Journal of Biomedical Science. 32(1). 94–94.
3.
Yang, Ching‐Yao, Jin‐Yuan Shih, Wei‐Yu Liao, et al.. (2023). Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system. European Journal of Cancer. 193. 113310–113310. 5 indexed citations
4.
Lin, Yen‐Ting, Chao‐Chi Ho, Wei‐Hsun Hsu, et al.. (2023). Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer. Cancer Medicine. 13(1). e6870–e6870. 4 indexed citations
5.
Hsu, Wei‐Hsun, et al.. (2023). Establishing a ROC curve model by body composition to predict active aging in the community care center elderly. AIP conference proceedings. 2778. 50008–50008. 1 indexed citations
6.
Liao, Bin-Chi, Wei‐Hsun Hsu, Ching‐Yao Yang, et al.. (2023). Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Oncology. 102(4). 318–326. 5 indexed citations
7.
Hsu, Wei‐Hsun, et al.. (2023). Factors associated with survival of patients with advanced lung cancer and long travel distances. Journal of the Formosan Medical Association. 123(2). 273–282.
8.
Silveira, Pablo A., Fiona Kupresanin, Wei‐Hsun Hsu, et al.. (2022). Anti-Mouse CD83 Monoclonal Antibody Targeting Mature Dendritic Cells Provides Protection Against Collagen Induced Arthritis. Frontiers in Immunology. 13. 784528–784528. 1 indexed citations
9.
Hsu, Wei‐Hsun, et al.. (2022). Necrotizing Fasciitis Extending to the Neck After Extracorporeal Shock Wave Lithotripsy: A Case Report. Iranian Journal of Radiology. 19(2). 1 indexed citations
10.
Liao, Bin-Chi, Wei‐Hsun Hsu, Jih‐Hsiang Lee, et al.. (2020). Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC. JTO Clinical and Research Reports. 2(1). 100099–100099. 1 indexed citations
11.
12.
Hsu, Wei‐Hsun, Xiaoliang Zhao, Jianquan Zhu, et al.. (2019). Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. Journal of Thoracic Oncology. 14(6). 1032–1045. 47 indexed citations
13.
14.
Li, Ziduo, Xinsheng Ju, Pablo A. Silveira, et al.. (2019). CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential. Frontiers in Immunology. 10. 1312–1312. 119 indexed citations
15.
Lin, Shu‐Yung, Ching‐Yao Yang, Bin-Chi Liao, et al.. (2018). Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. Journal of Cancer. 9(10). 1813–1820. 44 indexed citations
16.
17.
Rao, Guanhua, Mariaelena Pierobon, In‐Kyu Kim, et al.. (2017). Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Scientific Reports. 7(1). 7066–7066. 67 indexed citations
18.
Hsu, Wei‐Hsun, et al.. (2015). EMT is associated with, but does not drive resistance to ALK inhibitors among EML4‐ALK non‐small cell lung cancer. Molecular Oncology. 10(4). 601–609. 33 indexed citations
19.
Lee, Jih‐Hsiang, Yulin Lin, Wei‐Hsun Hsu, et al.. (2014). Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(9). 1385–1392. 36 indexed citations
20.
Melwanki, Mahaveer B., Wei‐Hsun Hsu, & Shang‐Da Huang. (2005). Determination of clenbuterol in urine using headspace solid phase microextraction or liquid–liquid–liquid microextraction. Analytica Chimica Acta. 552(1-2). 67–75. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ziyang Wang Breakdown of academic impact, for papers by Kazuaki Matsuoka Breakdown of academic impact, for papers by Miriam E. Mossoba Breakdown of academic impact, for papers by Virginia Belsúe Breakdown of academic impact, for papers by Max Sauter Breakdown of academic impact, for papers by Nima Taefehshokr Breakdown of academic impact, for papers by Guangjian Yang Breakdown of academic impact, for papers by Xiaofei Li Breakdown of academic impact, for papers by Peter E. Barker
Rankless by CCL
2026